Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Nivolumab |
Indication/Tumor Type | esophageal cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | esophageal cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with platinum and fluoropyrimidine-based chemotherapy is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with advanced untreated esophageal cancer with a CD274 (PD-L1) expression of CPS >/=5 (PMID: 38458658; ESMO.org). | 38458658 detail... |
CD274 positive | esophageal cancer | sensitive | Nivolumab | Guideline | Actionable | Opdivo (nivolumab) in combination with fluoropyrimidine and platinum-based chemotherapy is included in guidelines as first-line therapy for patients with advanced, untreated esophageal cancer expressing PD-L1 (CD274, CPS>=5) (PMID: 35914639; ESMO.org). | 35914639 detail... |
PubMed Id | Reference Title | Details |
---|---|---|
ESMO Clinical Practice Guidelines | Full reference... | |
ESMO Clinical Practice Guidelines | Full reference... | |
(35914639) | Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Full reference... |
(38458658) | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. | Full reference... |